Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL)
are distinct histologic types of B-cell NHL. Lenalidomide is an immunomodulatory agent
with direct and immune-mediated mechanisms of action, as well as clinical activity in
NHL. Recent studies in frontline and relapsed/refractory NHL show high activity for
lenalidomide plus rituximab (R2), supporting further study of this combination.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT01996865.
MAGNIFY (NCT01996865) is a phase 3b, multicenter, open-label study of patients with
grades 1-3b or transformed follicular lymphoma (FL), marginal zone lymphoma (MZL), or
mantle cell lymphoma (MCL) who received ≥1 prior therapy and had stage I-IV, measurable
disease. ~500 patients are planned for enrollment in 12 cycles of R2 induction, with a
projected ~314 patients with ≥SD after induction randomized (1:1) to two maintenance
arms. Induction includes oral lenalidomide 20 mg/day, days 1-21 per 28-day cycle
(d1-21/28) plus IV rituximab 375 mg/m2, days 1, 8, 15, and 22 of cycle 1 and day 1 of
cycles 3, 5, 7, 9, and 11 (28-day cycles). Patients are then randomized to maintenance
lenalidomide 10 mg/day, d1-21/28, cycles 13-30, plus rituximab 375 mg/m2, day 1 of cycles
13, 15, 17, 19, 21, 23, 25, 27, and 29 (R2, Arm A), or rituximab alone (same schedule,
Arm B). Patients receiving R2 maintenance after 18 cycles may continue maintenance
lenalidomide monotherapy 10 mg/day, d1-21/28 (per patient and/or investigator
discretion), until disease progression as tolerated. The primary endpoint is
progression-free survival (per modified 1999 IWG criteria). Secondary endpoints include
safety, overall survival, response rates, duration of response, and quality of life
(exploratory). Patients will be followed for ≥5 years after the last patient initiated
induction therapy. Enrollment in MAGNIFY began in March 2014; as of Jan 2016, 133
patients are enrolled.
Lead OrganizationCelgene Corporation
